Cetinal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetinal

Quick Facts

Property Description
Active Ingredient Cetirizine Hydrochloride
Pharmacological Class Second-generation H₁-Receptor Antagonist
Origin Synthetic (Piperazine Derivative)
Forms Tablet, Oral Solution, Syrup
General Use Mitigation of allergic reaction symptoms

Cetinal: Definition and Pharmacological Classification

Cetinal is a trade name for a medicine containing the active ingredient Cetirizine Hydrochloride, which functions as a targeted anti-allergic agent. Pharmacologically, the substance is classified as a second-generation H₁-receptor antagonist (antihistamine). The compound is a synthetic piperazine derivative developed through chemical synthesis, with its core identity characterized by its focused action.

Composition, Forms, and General Purpose

In most formulations, the primary therapeutic component is Cetirizine Hydrochloride, supplied as a single-ingredient product. It is available in multiple forms suitable for oral administration, including the solid tablet or film-coated tablet, and the liquid oral solution or syrup. This range provides flexibility, particularly for the pediatric population.

Its general purpose is to alleviate the common physical manifestations of a hypersensitivity reaction. The medicine achieves this by selectively blocking the action of histamine, thereby mitigating the systemic reaction associated with an allergic response. This targeted action is used for providing relief from symptoms like generalized itching and sneezing.

How Cetinal Differs from Other Antihistamines

Cetinal is distinguished within its class by its second-generation status, reflecting its highly selective antagonism of peripheral H₁ receptors. This targeted mechanism is intended to minimize the compound's penetration of the blood-brain barrier.

This structural advantage means the medicine retains effective anti-allergic activity while presenting a significantly reduced potential for central nervous system effects, such as the profound drowsiness often associated with older, first-generation antihistamine compounds.

Regulatory References

  1. Cetirizine - StatPearls - NIH
  2. Cetirizine: MedlinePlus Drug Information

What side effects are possible with Cetinal?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety constraints documented in official regulatory labeling for Cetinal (Cetirizine).

Adverse Reactions by Frequency and System-Organ Class

The possible side effects are officially categorized based on how often they occur:

  • Common (may affect up to 1 in 10 people): Somnolence (drowsiness), Fatigue, Headache, Dizziness, Dry mouth, Nausea, Pharyngitis.
  • Uncommon (may affect up to 1 in 100 people): Agitation, Diarrhoea, Pruritus (itching), Rash.
  • Rare (may affect up to 1 in 1,000 people): Hypersensitivity reactions, Tachycardia (fast heart rate), Confusion, Hepatic function abnormal (abnormal liver tests), Urticaria (hives).
  • Very Rare (may affect up to 1 in 10,000 people): Anaphylactic shock (a severe allergic reaction), Convulsions, Thrombocytopenia (low platelet count).

Specific Safety Constraints and Considerations

Official documents highlight the following safety restrictions and population-specific considerations:

  • Serious Adverse Reactions: The regulatory profile includes warnings for severe events, specifically Anaphylactic shock, Convulsions (seizures), and Hepatic function abnormal.
  • Use in Impaired Organ Function: Dose adjustments (reductions) are required for patients with impaired renal (kidney) or hepatic (liver) function. The medication is contraindicated in cases of severe renal impairment.
  • Discontinuation Pattern: There are reports of severe pruritus (itching) following the sudden discontinuation of the medication after long-term daily use.
  • Urinary Retention Risk: Caution is advised in patients with predisposing factors for urinary retention (difficulty emptying the bladder).

Safety notes emphasize that patients experiencing central nervous system effects such as somnolence should refrain from operating machinery or driving.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Cetinal (Cetirizine Hydrochloride) is primarily linked to dose-dependent central nervous system (CNS) effects. Ingestion exceeding five times the recommended daily dose is commonly cited in regulatory references as associated with overdose presentation.

System Affected Documented Overdose Manifestations
CNS Somnolence, Drowsiness, Restlessness, Agitation, Confusion, Tremor, Headache
Systemic Tachycardia (fast heart rate), Diarrhea, Nausea

Severe neurological outcomes documented in regulatory labeling include syncope (fainting) or convulsions (seizures). In the pediatric population, the primary observed effect is pronounced drowsiness and sedation; infants may exhibit restlessness followed by sedation.

When to Seek Immediate Medical Help The required emergency action is to immediately seek medical help or contact a Poison Control Center upon suspected overdose. Urgent medical attention is mandated by official guidance if severe, life-threatening symptoms are present, specifically including collapse, seizure, trouble breathing, or inability to be awakened.

Management procedures are limited to symptomatic and supportive treatment, as there is no known specific antidote to Cetirizine. Regulatory information also confirms that the compound cannot be effectively removed from the body by dialysis. Clinical observation, potentially including cardiac monitoring, is recommended for the management of large ingestions.

Therapeutic Uses of Cetinal

Cetinal is applied across therapeutic domains involving heightened physiological activity and systemic imbalance. It is used to help with symptom clusters related to Allergic Rhinitis (seasonal and perennial), Chronic Idiopathic Urticaria, and Allergic Conjunctivitis.

This medicine is applied in addressing the disruptive symptoms of the upper airways, such as frequent sneezing and runny nose, alongside ocular discomfort like itchy, watery eyes. It is relevant for easing acute or temporary skin manifestations and the recurrent episodes of chronic hives across various age groups.

“It supports symptomatic relief in conditions characterized by periods of heightened discomfort, such as intense allergic itching and swelling.”

This supportive relief helps maintain a sense of stability when symptoms are more noticeable, assisting with comfort during both episodic changes and persistent, year-round allergic periods.

Therapeutic Focus Block

Property Description
Therapeutic Focus: Support for Pruritus and Hives
Symptom Areas Nasal, Ocular, Dermatological
Relevant Clinical Context Seasonal and Persistent Allergies

Regulatory References

  1. Cetirizine - StatPearls - NIH

Eligibility and Restrictions for Use

Cetinal’s use is governed by official population eligibility rules defined by regulatory agencies. It is strictly contraindicated for any individual with a history of hypersensitivity or allergic reaction to cetirizine hydrochloride, its parent compound hydroxyzine, or any piperazine derivatives. Patients with severe renal impairment (creatinine clearance less than 10 ml/min) are also prohibited from using this medicine.

The medicine is approved for adults and adolescents. Pediatric eligibility starts from 6 months of age for oral solution formulations and specific indications; tablet use is generally restricted to children 6 years and older.

Use is conditional for certain populations. Patients with moderate renal impairment require a restricted, reduced dosage. Caution is recommended for those with underlying conditions that predispose them to urinary retention or who are epileptic or at risk of convulsions. Regulatory documents advise caution when prescribing Cetinal during pregnancy and lactation due to the drug's transfer into human breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory documentation for Cetinal (Cetirizine Hydrochloride) defines its interaction profile based on documented pharmacokinetic and pharmacodynamic patterns. No specific drug-drug combinations are officially classified as contraindicated for co-administration.

Pharmacodynamic Interactions

The official labeling highlights a pharmacodynamic interaction with substances that affect the central nervous system. Co-administration with Alcohol or other CNS Depressants (such as certain sedatives or tranquilizers) may lead to an additive effect. This documented effect may result in additional reductions in alertness and impairment of performance, particularly in sensitive patients.

Pharmacokinetic Interactions (Altered Exposure)

Certain medicines can alter the amount of Cetinal in the body. This includes co-administration with Ritonavir (600 mg twice daily), which is documented to increase the overall extent of Cetinal exposure by approximately 40%. Conversely, co-administration with Theophylline (400 mg once daily) causes a 16% decrease in the clearance of Cetinal.

Tested Substances with No Interaction

Pharmacokinetic studies confirmed that no significant interaction was observed when Cetinal was co-administered with medicines such as pseudoephedrine, antipyrine, ketoconazole, erythromycin, or azithromycin.

Food and Timing Constraints

When Cetinal is taken with food, the overall extent of absorption is not reduced. However, official regulatory documents state that food does decrease the rate of absorption, resulting in a delayed time to reach peak plasma concentration. No mandatory timing separation rules for administration are specified.

Mechanism of Action

Cetinal is a highly selective antagonist of the peripheral histamine H1 receptor. Following systemic distribution, the molecule binds competitively to the H1 receptor located on target tissues, including respiratory smooth muscle, vascular endothelial cells, and various immune cells. This binding action prevents the endogenous ligand, histamine, from occupying and activating the receptor.

The H1 receptor is a Gq protein-coupled receptor (Gq-GPCR). By preventing histamine binding, Cetinal inhibits the downstream signaling cascade typically initiated by Gq activation, which involves the mobilization of intracellular calcium ( Ca^2+) and the activation of protein kinase C ( PKC). The resulting intracellular consequence is the suppression of H1-mediated cell responses, such as smooth muscle contraction and the increase in vascular permeability, primarily at peripheral sites. System-level physiological modulation includes reduction of localized tissue fluid extravasation and inhibition of H1-dependent bronchoconstriction. Furthermore, Cetinal exhibits H1-independent effects, specifically modulating the NF-kappa B pathway to regulate chemokine and cytokine release, reducing the recruitment and migration of inflammatory cells, such as eosinophils, to target tissues.

Dosage and Administration Information

How to Use Cetinal: Administration Guidelines

The usage of Cetinal (Cetirizine Hydrochloride) involves specific administration routes, standardized dose limits, and required adjustments. The medicine is available in various forms for oral, intravenous (IV), and topical ophthalmic use, which determines the method of administration.

For oral administration, the standard dosing regimen for adults and children 12 years and older is 10 mg once daily, although a 5 mg once daily dose may be appropriate for less severe symptoms. The oral forms, including tablets and solutions, can be taken with or without food.

Dosing and Frequency Patterns

Age Group Standard Oral Regimen Frequency Pattern
Adults (ge 12 years) 10 mg or 5 mg Once daily
Children (6 to 11 years) 5 mg to 10 mg Once daily or Divided Twice Daily

The standard pattern is once daily (every 24 hours) for both oral maintenance and the IV injectable form, which is administered as a 1 to 2 minute intravenous push. For children 6 to 11 years, the total daily dose may be taken either as a single 10 mg dose or as 5 mg administered twice daily.

Population-Specific Use

Dose adjustments are required for adult patients with moderate to severe renal impairment to prevent accumulation. For these patients, the oral dose is typically reduced to 5 mg once daily or less, based on the degree of kidney function. If an oral dose is missed, the standard protocol is to take it as soon as remembered, but strictly not to take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cetinal

The clinical evaluation of Cetinal (cetirizine) was primarily explored through Randomized Controlled Trials (RCTs) and systematic reviews, which are the study types that examined the approved indications. This research was evaluated in settings exploring temporary physiological imbalance, specifically focusing on conditions characterized by fluctuating or episodic manifestations of allergy.


Evidence for Use in Seasonal and Perennial Allergies (Allergic Rhinitis)

Research examined Cetinal in the context of symptoms associated with both Seasonal Allergic Rhinitis (SAR) (hay fever) and Perennial Allergic Rhinitis (PAR) (year-round allergies). These studies focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies monitored patient-reported outcomes describing perceived discomfort using composite scales known as Total Symptom Scores (TSS). Research so far describes patterns of change in these scores when Cetinal was observed in the studied populations, including comparisons to placebo in the research setting. Trials also explored differences in health-related Quality of Life (QOL) as an outcome axis alongside symptom changes.

A key limitation is that trials assessing short-term or episodic symptom patterns in SAR are often short-term, typically lasting 7 to 14 days, which means follow-up durations were limited. This contributes to understanding short-term changes but means long-term effects are not fully established.


Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

Cetinal was evaluated in studies focusing on Chronic Idiopathic Urticaria (CIU), a condition presenting with cycles of stability and flare-ups. Research examined specific outcomes related to physical discomfort, including the intensity of pruritus (itching) and the characteristics of the lesions (hives).

Systematic reviews and meta-analyses monitored symptom change over time and reported data related to outcomes related to physical discomfort during short- and intermediate-term observation periods. The evidence quality varies across studies for some secondary outcomes like Quality of Life.


Evidence in Special Populations

Research explored how Cetinal was studied for use across a wide age range. The available research was evaluated in both adults and children. Studies monitored pediatric populations, with research conducted in children as young as 6 months of age for conditions involving periods of heightened symptoms, such as CIU and PAR. However, during early regulatory assessments, a need for more focused research exploring specific patterns in the elderly population was observed in some studies, highlighting a research limitation.

Key Studies & References PFIZER's REACTINE (CETIRIZINE) IS EFFECTIVE FOR ALLERGIC RHINITIS AND URTICARIA, FDA COMMITTEE AGREES; PANEL ASKS FOR FURTHER DATA ON SEDATIVE EFFECTS

Frequently Asked Questions (FAQ)

Common questions about Cetinal (FAQ)

Q: How quickly can a person expect Cetinal to start working for allergy symptoms?

A: Official information indicates that the effects of Cetinal are generally observed within 30 minutes to one hour after administration. It is documented in regulatory materials that taking the medicine with food may slow down the rate at which it is absorbed, which could potentially delay the time to onset.


Q: Is Cetinal generally considered a long-term treatment or is it for short-term use?

A: The medicine is approved for conditions that may require both short-term relief, such as seasonal allergies, and chronic management, such as chronic hives. Official documents note a limitation on long-term follow-up data in some short-term trials, but the scope of approval covers both types of symptom management.


Q: Can older adults use Cetinal, or do they need special considerations?

A: Official product information advises that older adults, especially those 65 years and older, should be aware of potential considerations. Regulatory documents state that older adults may exhibit increased sensitivity, and dose adjustments are officially required in cases of reduced kidney or liver function, as the drug is primarily cleared by the kidneys.


Q: Does taking Cetinal at night reduce the chances of daytime side effects?

A: Due to the potential for somnolence, or drowsiness, as a common side effect, taking the medicine in the evening is a strategy that is sometimes noted in informational guidance to help mitigate the risk of daytime sedation. This relates to the drug's effect on the central nervous system.


Q: What is the intended duration of action for a single dose of Cetinal?

A: Studies and official information indicate that the pharmacological effects of a single dose of Cetinal generally last for about 24 hours. This duration of action supports the standard once-daily dosing regimen of the medicine.


Q: What is the risk of an allergic reaction to the drug itself?

A: Official regulatory documents classify the occurrence of a Hypersensitivity reaction (an allergic reaction) as rare (up to 1 in 1,000 people) and a severe systemic reaction like Anaphylactic shock as very rare (up to 1 in 10,000 people). This information is derived from the official safety documentation.


Q: Can Cetinal cause mood changes like anxiety or depression, as mentioned in user reports?

A: Official regulatory documents list Agitation (uncommon) and Confusion (rare) as documented possible side effects affecting the nervous system. However, official regulatory lists do not explicitly name anxiety or depression among the documented side effects.


Q: Is there a warning about severe itching if Cetinal is stopped suddenly after long-term use?

A: Yes, regulatory bodies have noted reports of severe pruritus (itching) that may occur following the sudden discontinuation of the medicine after long-term daily use. This is a safety constraint documented in regulatory product information.


Q: What kind of studies have been performed to understand the effects of Cetinal?

A: The effects of Cetinal were primarily studied through controlled research designs, as detailed in regulatory materials. These included Randomized Controlled Trials (RCTs) and systematic reviews that focused on the approved indications, such as allergic rhinitis and chronic hives.


Q: What happens if someone accidentally misses a dose of Cetinal?

A: Official patient guidance states that a missed dose should be taken as soon as remembered. The guidance specifically advises not to take a double dose to compensate for the dose that was missed.


Q: Can Cetinal be used to help with itching and hives that are not caused by allergies?

A: Cetinal is approved for treating symptoms related to Chronic Idiopathic Urticaria (CIU), a form of chronic hives where the underlying cause is unknown. The approved use is defined by the specific allergic and urticaria conditions named in the official labeling.


Q: Does Cetinal interact with common over-the-counter pain relievers like ibuprofen or paracetamol?

A: While official studies have not found significant interactions with several other common medicines, the regulatory documents do not contain specific findings regarding the interaction profile with common over-the-counter pain relievers such as ibuprofen or paracetamol.


Q: What is the difference between prescription Cetinal and the over-the-counter form?

A: The difference between prescription and over-the-counter (OTC) forms is typically related to the approved dosing strengths, the maximum package size, and the minimum age limits for use without a doctor's supervision. The active ingredient remains the same in both forms.


Q: Are there any long-term health concerns associated with taking Cetinal daily for years?

A: Clinical trials defining effects over very long periods are limited in duration, as is common for many medicines. A specific concern noted for long-term use is the potential risk of severe itching upon sudden discontinuation.


Q: Are there any specific organs, like the liver or kidneys, that are especially important to monitor when taking Cetinal?

A: The kidneys and liver are important because regulatory documents specify that dose adjustments are officially required in cases of impaired function in these organs. This is due to the drug being primarily eliminated from the body via the kidneys.


Q: What is the connection between Cetinal and other similar drug names like Levocetinal?

A: Levocetinal (Levocetirizine) is chemically related; it is described in scientific summaries as the main active component, or levorotatory enantiomer, of Cetinal (Cetirizine). This relates to their chemical structure and biological activity.


Q: Is Cetinal also used to treat symptoms of the common cold, or only allergies?

A: The approved indications for Cetinal are specific to symptoms caused by allergic reactions (allergic rhinitis and chronic hives). It is not formally approved for treating symptoms related to the common cold.


Q: What is the process for stopping Cetinal after using it consistently for a long time?

A: Official regulatory documents only contain a safety warning about the potential for severe itching following sudden discontinuation after long-term use. No specific, directive clinical cessation process is provided in official labeling beyond the safety warning.


Q: Are there any specific warnings for individuals who have a history of seizures or epilepsy when considering Cetinal?

A: Official regulatory documents advise that caution should be exercised when the medicine is used by patients with a history of epilepsy or those who are at risk of having convulsions (seizures).


Q: What is the function of histamine in the body, which Cetinal works to block?

A: Histamine is a natural substance that the body releases during an allergic reaction, which then binds to receptors to cause symptoms like itching, sneezing, and swelling. Cetinal works by blocking this binding action, thereby helping to mitigate the allergic response.


Q: Does taking Cetinal with or without food change how the medicine works?

A: Official documentation states that taking the medicine with food does not reduce the overall amount of medicine absorbed. However, it is documented to decrease the rate of absorption, which may result in a delay in the time needed to reach peak concentration in the body.


Q: What is the recommended storage condition for Cetinal?

A: Official storage instructions recommend that the medicine be kept at controlled room temperature, generally defined as 20 C to 25 C. It must also be protected from moisture and stored securely out of the sight and reach of children.


Q: Does Cetinal have any documented effects on blood pressure?

A: Clinical safety data indicates that Cetinal, when used alone, is not associated with cardiotoxicity or significant effects on blood pressure. Warnings related to blood pressure are generally noted for combination products that include decongestant ingredients.


Q: Are the side effects of Cetinal different for children compared to adults?

A: Official regulatory sources indicate that children may have a higher likelihood of experiencing certain side effects compared to adults. These include specific effects such as diarrhoea or symptoms related to the nose and throat.


Q: Can Cetinal be taken at the same time as nasal steroid sprays for allergies?

A: Formal drug interaction assessments have been conducted and have not found a clinically significant pharmacokinetic interaction documented when Cetinal is co-administered with common nasal corticosteroids.


Q: Is there any information available on Cetinal's impact on long-term fertility?

A: Official health information indicates that there is no evidence to demonstrate that Cetinal reduces long-term fertility in either men or women.


Q: Does Cetinal interact with any medicines used for asthma or breathing problems, like theophylline?

A: Yes, pharmacokinetic studies have documented a specific interaction with the medicine Theophylline. Co-administration with Theophylline causes a 16% decrease in the clearance of Cetinal from the body.

How should Cetinal be stored and disposed of?

The storage and disposal of Cetinal (Cetirizine Hydrochloride) must strictly follow official regulatory instructions to maintain product stability and safety.

Storage Conditions

Temperature

Store the medicine at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). Do not allow liquid formulations (syrups/solutions) to freeze.

Protection and Handling

Tablets must be protected from moisture and high humidity, while liquid forms should be protected from light. Keep the product in its original container, and ensure multi-dose liquid containers are tightly closed after use.

Safety

All forms of this medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Cetinal must be disposed of according to local regulatory requirements for waste medicine. Do not throw the medicine into household waste or wastewater unless instructed otherwise by a local authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetinal found in:

A-Z Index: